Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
EMERGING-CTONG 1103
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
- NCT01407822 ↗
- Unknown
- Guangdong Association of Clinical Trials
- Focused
We haven't built an HCP commentary report on EMERGING-CTONG 1103 (erlotinib in stage IIIA-N2 EGFR-mutant non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EMERGING-CTONG 1103 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)
- Phase
- Phase 2/Phase 3
- Status
- Unknown
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Erlotinib; Gemcitabine/cisplatin
- Arms
- Erlotinib arm · Experimental
- Chemo arm · Active comparator
- Enrollment
- 72
- Primary outcomes
- The objective response rate (ORR) in neoadjuvant treatment
- Sponsor
- Guangdong Association of Clinical Trials with Guangdong Provincial People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Jilin Provincial Tumor Hospital, Jiangsu Cancer Institute & Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital & Institute, Sun Yat-sen University, West China Hospital, The First Affiliated Hospital of Dalian Medical University, Peking University People's Hospital, Xi'an Jiaotong University, Shanghai Zhongshan Hospital, Guangzhou General Hospital of Guangzhou Military Command, The First Affiliated Hospital of Guangzhou Medical University, Fujian Medical University Union Hospital, Linyi Tumour Hospital, Northern Jiangsu People's Hospital
- Start
- Dec 5, 2011
- Primary completion
- Apr 24, 2018
- Results posted
- No
- Registry record
- NCT01407822 · updated Sep 11, 2018
Publications
linked from the registry- Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol. 2008 Sep 1;26(25):4205-7. doi: 10.1200/JCO.2008.16.3709. No abstract available. PubMed 18757336
- Takamochi K, Suzuki K, Sugimura H, Funai K, Mori H, Bashar AH, Kazui T. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer. 2007 Oct;58(1):149-55. doi: 10.1016/j.lungcan.2007.04.016. Epub 2007 Jun 4. PubMed 17548126
- Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010 Nov;5(11):1806-14. doi: 10.1097/JTO.0b013e3181f38f70. PubMed 20881637
- Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res. 2011 May 15;17(10):3500-6. doi: 10.1158/1078-0432.CCR-10-2102. Epub 2011 May 10. PubMed 21558399
- Zhong WZ, Yan HH, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang XZ, Yan WP, Liao RQ, Yang JJ, Zhang XC, Liu SY, Zhou Q, Wu YL. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PubMed 36823150
- Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, Yan HH, Liao RQ, Yang JJ, Zhang XC, Zhou Q, Wu YL. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13. PubMed 31194613